Pointer: The application of prophylactic antibodies for rhinovirus infections

Antiviral Chemistry and Chemotherapy

Volumn 23, Issue 5, 2014, Pages 173-177

  Privolizzi, Riccardo ^a   Solari, Roberto ^b   Johnston, Sebastian L ^b   McLean, Gary R ^a,b  

^a LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ABSENTEEISM; ANTIBODY RESPONSE; ARTICLE; CHRONIC LUNG DISEASE; COMMON COLD; COST OF ILLNESS; DISEASE EXACERBATION; HUMAN; INFECTION PREVENTION; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PRODUCTIVITY; RHINOVIRUS; RHINOVIRUS INFECTION; UPPER RESPIRATORY TRACT INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

ANTIBODIES, MONOCLONAL; HUMANS; PRE-EXPOSURE PROPHYLAXIS; RESPIRATORY TRACT INFECTIONS; RHINOVIRUS;

EID: 84897499291     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2578     Document Type: Article

References (52)

1. Schroeder HW, Jr., Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125 Suppl 2: S41-S52.
2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
3. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012; 12: 615-622.
4. Cooper MD, Herrin BR. How did our complex immune system evolve? Nat Rev Immunol 2010; 10: 2-3.
5. Lewis JK, Bothner B, Smith TJ, Siuzdak G. Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A 1998; 95: 6774-6778.
6. Marlin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber W, Merluzzi VJ. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 1990; 344: 70-72.
7. Rollinger JM, Schmidtke M. The human rhinovirus: humanpathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev 2011; 31: 42-92.
8. Perkins JC, Tucker DN, Knope HL, et al. Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. Am J Epidemiol 1969; 90: 319-326.
9. Fox JP. Is a rhinovirus vaccine possible? Am J Epidemiol 1976; 103: 345-354.
10. Smith TJ, Chase ES, Schmidt TJ, Olson NH, Baker TS. Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. Nature 1996; 383: 350-354.
11. McLean GR, Walton RP, Shetty S, et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Res 2012; 95: 193-201.
12. Niespodziana K, Napora K, Cabauatan C, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. FASEB J 2012; 26: 1001-1008.
13. Edlmayr J, Niespodziana K, Popow-Kraupp T, et al. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur Respir J 2011; 37: 44-52.
14. Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol 2009; 83: 7040-7048.
15. Greenberg SB. Rhinovirus and coronavirus infections. Semin Respir Crit Care Med 2007; 28: 182-192.
16. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310: 1225-1229.
17. Rhinoviruses: a numbering system. Nature 1967; 213: 761-762.
18. Conant RM, Hamparian VV. Rhinoviruses: basis for a numbering system. 1. HeLa cells for propagationand serologic procedures. J Immunol 1968; 100: 107-113.
19. Conant RM, Hamparian VV. Rhinoviruses: basis for a numbering system. II. Serologic characterization of prototype strains. J Immunol 1968; 100: 114-119.
20. Palmenberg AC, Spiro D, Kuzmickas R, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009; 324: 55-59.
21. Lee WM, Kiesner C, Pappas T, et al. A diverse group of previously unrecognized human rhinoviruses are common causes of respiratory illnesses in infants. PLoS ONE 2007; 2: e966.
22. Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56: 839-847.
23. Hofer F, Gruenberger M, Kowalski H, et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci U S A 1994; 91: 1839-1842.
24. Rossmann MG, Arnold E, Erickson JW, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985; 317: 145-153.
25. Carey BS, Barclay WS, Russell SM, Tyrrell DA. The specificity of antibodies induced by infection with rhinovirus type 2. J Med Virol 1992; 36: 251-258.
26. Barclay WS, al-Nakib W, Higgins PG, Tyrrell DA. The time course of the humoral immune response to rhinovirus infection. Epidemiol Infect 1989; 103: 659-669.
27. Kainulainen L, Vuorinen T, Rantakokko-Jalava K, Osterback R, Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinaemia. J Allergy Clin Immunol 2010; 126: 120-126.
28. Peltola V, Waris M, Kainulainen L, Kero J, Ruuskanen O. Virus shedding after human rhinovirus infection in children, adults and patients with hypogammaglobulinaemia. Clin Microbiol Infect 2013; 19: E322-E327.
29. Sherry B, Mosser AG, Colonno RJ, Rueckert RR. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol 1986; 57: 246-257.
30. Appleyard G, Russell SM, Clarke BE, Speller SA, Trowbridge M, Vadolas J. Neutralization epitopes of human rhinovirus type 2. J Gen Virol 1990; 71: 1275-1282.
31. Barnett PV, Rowlands DJ, Parry NR. Characterization of monoclonal antibodies raised against a synthetic peptide capable of inducing a neutralizing response to human rhinovirus type 2. J Gen Virol 1993; 74: 1295-1302.
32. Skern T, Neubauer C, Frasel L, et al. A neutralizing epitope on human rhinovirus type 2 includes amino acid residues between 153 and 164 of virus capsid protein VP2. J Gen Virol 1987; 68: 315-323.
33. Cooney MK, Fox JP, Kenny GE. Antigenic groupings of 90 rhinovirus serotypes. Infect Immun 1982; 37: 642-647.
34. Hastings GZ, Speller SA, Francis MJ. Neutralizing antibodies to human rhinovirus produced in laboratory animals and humans that recognize a linear sequence from VP2. J Gen Virol 1990; 71: 3055-3059.
35. McCray J, Werner G. Different rhinovirus serotypes neutralized by antipeptide antibodies. Nature 1987; 329: 736-738.
36. Francis MJ, Hastings GZ, Sangar DV, et al. A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2. J Gen Virol 1987; 68: 2687-2691.
37. Sherry B, Rueckert R. Evidence for at least two dominant neutralization antigens on human rhinovirus 14. J Virol 1985; 53: 137-143.
38. Smith TJ, Olson NH, Cheng RH, Chase ES, Baker TS. Structure of a human rhinovirus-bivalently bound antibody complex: implications for viral neutralization and antibody flexibility. Proc Natl Acad Sci U S A 1993; 90: 7015-7018.
39. Tormo J, Blaas D, Parry NR, Rowlands D, Stuart D, Fita I. Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2. EMBO J 1994; 13: 2247-2256.
40. Vlasak M, Blomqvist S, Hovi T, Hewat E, Blaas D. Sequence and structure of human rhinoviruses reveal the basis of receptor discrimination. J Virol 2003; 77: 6923-6930.
41. Laine P, Blomqvist S, Savolainen C, Andries K, Hovi T. Alignment of capsid protein VP1 sequences of all human rhinovirus prototype strains: conserved motifs and functional domains. J Gen Virol 2006; 87: 129-138.
42. Ledford RM, Patel NR, Demenczuk TM, et al. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsidbinding compounds. J Virol 2004; 78: 3663-3674.
43. Reading SA, Dimmock NJ. Neutralization of animal virus infectivity by antibody. Arch Virol 2007; 152: 1047-1059.
44. Herrin BR, Alder MN, Roux KH, et al. Structure and specificity of lamprey monoclonal antibodies. Proc Natl Acad Sci U S A 2008; 105: 2040-2045.
45. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007; 77: 13-22.
46. Hodits RA, Nimpf J, Pfistermueller DM, et al. An antibody fragment from a phage display library competes for ligand binding to the low density lipoprotein receptor family and inhibits rhinovirus infection. J Biol Chem 1995; 270: 24078-24085.
47. Charles CH, Luo GX, Kohlstaedt LA, et al. Prevention of human rhinovirus infection by multivalent fab molecules directed against ICAM-1. Antimicrob Agents Chemother 2003; 47: 1503-1508.
48. Traub, S, Nikonova A, Carruthers A, et al. An anti-human ICAM-1 antibody inhibits rhinoviral exacerbation of lung inflammation. PLoS Pathogens 2013; in press.
49. Bartlett NW, Walton RP, Edwards MR, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 2008; 14: 199-204.
50. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25: 1134-1143.
51. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol 2012; 12: 709-719.
52. Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996; 154: 654-660.